Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SY-4798
- Development stage
- Phase 1
- Lead developer
- Shouyao Holdings
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SY-4798 is a novel investigational drug being developed for advanced solid tumors, particularly focusing on liver cancer. It is a highly specific and potent oral inhibitor of Fibroblast Growth Factor Receptor 4 (FGFR4), a protein that plays a significant role in certain cancer types. SY-4798 functions as a selective antagonist of FGFR4 tyrosine kinase, aiming to block signaling pathways that promote tumor growth and survival. The drug is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with FGF19-positive advanced solid tumors.
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)
Beyond the preview
Go deeper on SY-4798.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SY-4798.